MTOR kinase inhibitors as potential cancer therapeutic drugs

Cancer Letters

Volumn 340, Issue 1, 2013, Pages 1-8

  Sun, Shi Yong ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Inhibitors; Kinase; MTOR

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 3 YL) 1H INDOL 5 OL; 3 (2 AMINO 5 BENZOXAZOLYL) 1 (1 METHYLETHYL) 1H PYRAZOLO[3,4 D]PYRIMIDIN 4 AMINE; 4 (4 AMINO 5 (7 METHOXY 1H INDOL 2 YL)IMIDAZO[5,1 F][1,2,4]TRIAZIN 7 YL)CYCLOHEXANECARBOXYLIC ACID; 4 [6 [4 [(METHOXYCARBONYL)AMINO]PHENYL] 4 (4 MORPHOLINYL) 1H PYRAZOLO[3,4 D]PYRIMIDIN 1 YL] 1 PIPERIDIN ECARBOXYLIC ACID METHYL ESTER; 6 (1H INDOL 5 YL) 4 MORPHOLINO 1 [1 (PYRIDIN 3 YLMETHYL)PIPERIDIN 4 YL] 1H PYRAZOLO[3,4 D]PYRIMIDINE; ALPHA CD40 ANTIBODY; ANTIBODY; ANTINEOPLASTIC AGENT; AZD 2014; AZD 8055; BORTEZOMIB; CETUXIMAB; DASATINIB; ERLOTINIB; EVEROLIMUS; FUSED CARBON NITROGEN HETEROCYCLE; INK 128; KU 0063794; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHYL 4 [4 MORPHOLINO 1 [1 (PYRIDIN 3 YLMETHYL)PIPERIDIN 4 YL] 1H PYRAZOLO[3,4 D]PYRIMIDIN 6 YL]PHENYLCARBAMATE; MLN 0128; PROTEIN SERINE THREONINE KINASE INHIBITOR; QUINOLINE DERIVATIVE; RAPAMYCIN; SELUMETINIB; TORIN 1; TORIN 2; UNCLASSIFIED DRUG; UNINDEXED DRUG; WAY 600; WYE 354; WYE 687; [5 [2 (2,6 DIMETHYLMORPHOLINO) 4 MORPHOLINOPYRIDO[2,3 D]PYRIMIDIN 7 YL] 2 METHOXYPHENYL]METHANOL;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; AUTOPHAGY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CHILDHOOD CANCER; COLON CANCER; COLORECTAL CARCINOMA; CONCENTRATION RESPONSE; CYTOSTASIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; FATIGUE; FEEDBACK SYSTEM; HEAD AND NECK CANCER; HUMAN; IC 50; KIDNEY METASTASIS; LEUKEMIA; LUNG CANCER; LUNG TUMOR; MONOTHERAPY; MUTATION; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SHORT SURVEY; SIDE EFFECT; SIGNAL TRANSDUCTION; SOLID TUMOR;

MAMMALIA; RAPTORES;

EID: 84883787742     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.06.017     Document Type: Review

References (69)

1. Marone R., Cmiljanovic V., Giese B., Wymann M.P. Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim. Biophys. Acta 2008, 1784:159-185.
2. Bjornsti M.A., Houghton P.J. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer 2004, 4:335-348.
3. Shaw R.J., Cantley L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006, 441:424-430.
4. Guertin D.A., Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12:9-22.
5. Alessi D.R., Pearce L.R., Garcia-Martinez J.M. New insights into mTOR signaling: mTORC2 and beyond. Sci. Signal. 2009, 2:pe27.
6. Sabatini D.M. MTOR and cancer: insights into a complex relationship. Nat. Rev. Cancer 2006, 6:729-734.
7. Abraham R.T., Gibbons J.J. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin. Cancer Res. 2007, 13:3109-3114.
8. Zhang Y.J., Duan Y., Zheng X.F. Targeting the mTOR kinase domain: the second generation of mTOR inhibitors. Drug Discov. Today 2011, 16:325-331.
9. Bhagwat S.V., Crew A.P. Novel inhibitors of mTORC1 and mTORC2. Curr. Opin. Investig. Drugs 2010, 11:638-645.
10. Garcia-Echeverria C. Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment. Bioorg. Med. Chem. Lett. 2010, 20:4308-4312.
11. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., Staroslawska E., Sosman J., McDermott D., Bodrogi I., Kovacevic Z., Lesovoy V., Schmidt-Wolf I.G., Barbarash O., Gokmen E., O'Toole T., Lustgarten S., Moore L., Motzer R.J. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 2007, 356:2271-2281.
12. Amato R.J., Jac J., Giessinger S., Saxena S., Willis J.P. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 2009, 115:2438-2446.
13. Motzer R.J., Escudier B., Oudard S., Hutson T.E., Porta C., Bracarda S., Grunwald V., Thompson J.A., Figlin R.A., Hollaender N., Urbanowitz G., Berg W.J., Kay A., Lebwohl D., Ravaud A. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456.
14. Yao J.C., Shah M.H., Ito T., Bohas C.L., Wolin E.M., Van Cutsem E., Hobday T.J., Okusaka T., Capdevila J., de Vries E.G., Tomassetti P., Pavel M.E., Hoosen S., Haas T., Lincy J., Lebwohl D., Oberg K. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 2011, 364:514-523.
15. Baselga J., Campone M., Piccart M., Burris H.A., Rugo H.S., Sahmoud T., Noguchi S., Gnant M., Pritchard K.I., Lebrun F., Beck J.T., Ito Y., Yardley D., Deleu I., Perez A., Bachelot T., Vittori L., Xu Z., Mukhopadhyay P., Lebwohl D., Hortobagyi G.N. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 2012, 366:520-529.
16. LoPiccolo J., Blumenthal G.M., Bernstein W.B., Dennis P.A. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist. Updat. 2008, 11:32-50.
17. Chiang G.G., Abraham R.T. Targeting the mTOR signaling network in cancer. Trends Mol. Med. 2007, 13:433-442.
18. Sun S.Y., Rosenberg L.M., Wang X., Zhou Z., Yue P., Fu H., Khuri F.R. Activation of Akt and eIF4E Survival Pathways by Rapamycin-Mediated Mammalian Target of Rapamycin Inhibition. Cancer Res. 2005, 65:7052-7058.
19. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., Lane H., Hofmann F., Hicklin D.J., Ludwig D.L., Baselga J., Rosen N. MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006, 66:1500-1508.
20. Wang X., Hawk N., Yue P., Kauh J., Ramalingam S.S., Fu H., Khuri F.R., Sun S.Y. Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy. Cancer Biol. Ther. 2008, 7:1952-1958.
21. Carracedo A., Ma L., Teruya-Feldstein J., Rojo F., Salmena L., Alimonti A., Egia A., Sasaki A.T., Thomas G., Kozma S.C., Papa A., Nardella C., Cantley L.C., Baselga J., Pandolfi P.P. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 2008.
22. Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101.
23. Guertin D.A., Stevens D.M., Saitoh M., Kinkel S., Crosby K., Sheen J.H., Mullholland D.J., Magnuson M.A., Wu H., Sabatini D.M. MTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 2009, 15:148-159.
24. Lee K., Nam K.T., Cho S.H., Gudapati P., Hwang Y., Park D.S., Potter R., Chen J., Volanakis E., Boothby M. Vital roles of mTOR complex 2 in Notch-driven thymocyte differentiation and leukemia. J. Exp. Med. 2012, 209:713-728.
25. Guertin D.A., Sabatini D.M. The pharmacology of mTOR inhibition. Sci. Signal. 2009, 2:pe24.
26. Sparks C.A., Guertin D.A. Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene 2010, 29:3733-3744.
27. Richard D.J., Verheijen J.C., Zask A. Recent advances in the development of selective, ATP-competitive inhibitors of mTOR. Curr. Opin. Drug Discov. Devel. 2010, 13:428-440.
28. Feldman M.E., Apsel B., Uotila A., Loewith R., Knight Z.A., Ruggero D., Shokat K.M. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 2009, 7:e38.
29. Yu K., Toral-Barza L., Shi C., Zhang W.G., Lucas J., Shor B., Kim J., Verheijen J., Curran K., Malwitz D.J., Cole D.C., Ellingboe J., Ayral-Kaloustian S., Mansour T.S., Gibbons J.J., Abraham R.T., Nowak P., Zask A. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res. 2009.
30. Garcia-Martinez J.M., Moran J., Clarke R.G., Gray A., Cosulich S.C., Chresta C.M., Alessi D.R. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem. J. 2009, 421:29-42.
31. Thoreen C.C., Kang S.A., Chang J.W., Liu Q., Zhang J., Gao Y., Reichling L.J., Sim T., Sabatini D.M., Gray N.S. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 2009, 284:8023-8032.
32. Hoang B., Frost P., Shi Y., Belanger E., Benavides A., Pezeshkpour G., Cappia S., Guglielmelli T., Gera J., Lichtenstein A. Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. Blood 2010, 116:4560-4568.
33. Chresta C.M., Davies B.R., Hickson I., Harding T., Cosulich S., Critchlow S.E., Vincent J.P., Ellston R., Jones D., Sini P., James D., Howard Z., Dudley P., Hughes G., Smith L., Maguire S., Hummersone M., Malagu K., Menear K., Jenkins R., Jacobsen M., Smith G.C., Guichard S., Pass M. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 2010, 70:288-298.
34. Liu Q., Kirubakaran S., Hur W., Niepel M., Westover K., Thoreen C.C., Wang J., Ni J., Patricelli M.P., Vogel K., Riddle S., Waller D.L., Traynor R., Sanda T., Zhao Z., Kang S.A., Zhao J., Look A.T., Sorger P.K., Sabatini D.M., Gray N.S. Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics. J. Biol. Chem. 2012, 287:9742-9752.
35. Janes M.R., Limon J.J., So L., Chen J., Lim R.J., Chavez M.A., Vu C., Lilly M.B., Mallya S., Ong S.T., Konopleva M., Martin M.B., Ren P., Liu Y., Rommel C., Fruman D.A. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat. Med. 2010, 16:205-213.
36. Zeng Z., Shi Y.X., Tsao T., Qiu Y., Kornblau S.M., Baggerly K.A., Liu W., Jessen K., Liu Y., Kantarjian H., Rommel C., Fruman D.A., Andreeff M., Konopleva M. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment. Blood 2012, 120:2679-2689.
37. Blaser B., Waselle L., Dormond-Meuwly A., Dufour M., Roulin D., Demartines N., Dormond O. Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells. BMC Cancer 2012, 12:86.
38. Shao H., Gao C., Tang H., Zhang H., Roberts L.R., Hylander B.L., Repasky E.A., Ma W.W., Qiu J., Adjei A.A., Dy G.K., Yu C. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo. J. Hepatol. 2012, 56:176-183.
39. Hsieh A.C., Liu Y., Edlind M.P., Ingolia N.T., Janes M.R., Sher A., Shi E.Y., Stumpf C.R., Christensen C., Bonham M.J., Wang S., Ren P., Martin M., Jessen K., Feldman M.E., Weissman J.S., Shokat K.M., Rommel C., Ruggero D. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 2012, 485:55-61.
40. Maiso P., Liu Y., Morgan B., Azab A.K., Ren P., Martin M.B., Zhang Y., Sacco A., Ngo H., Azab F., Quang P., Rodig S.J., Lin C.P., Roccaro A.M., Rommel C., Ghobrial I.M. Defining the role of TORC1/2 in multiple myeloma. Blood 2011, 118:6860-6870.
41. Janes M.R., Vu C., Mallya S., Shieh M.P., Limon J.J., Li L.S., Jessen K.A., Martin M.B., Ren P., Lilly M.B., Sender L.S., Liu Y., Rommel C., Fruman D.A. Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia. Leukemia 2012.
42. Garcia-Garcia C., Ibrahim Y.H., Serra V., Calvo M.T., Guzman M., Grueso J., Aura C., Perez J., Jessen K., Liu Y., Rommel C., Tabernero J., Baselga J., Scaltriti M. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. Clin. Cancer Res. 2012, 18:2603-2612.
43. Garcia-Martinez J.M., Alessi D.R. MTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem. J. 2008, 416:375-385.
44. Yan L., Mieulet V., Lamb R.F. MTORC2 is the hydrophobic motif kinase for SGK1. Biochem. J. 2008, 416:e19-21.
45. Willems L., Chapuis N., Puissant A., Maciel T.T., Green A.S., Jacque N., Vignon C., Park S., Guichard S., Herault O., Fricot A., Hermine O., Moura I.C., Auberger P., Ifrah N., Dreyfus F., Bonnet D., Lacombe C., Mayeux P., Bouscary D., Tamburini J. The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Leukemia 2012, 26:1195-1202.
46. Houghton P.J., Gorlick R., Kolb E.A., Lock R., Carol H., Morton C.L., Keir S.T., Reynolds C.P., Kang M.H., Phelps D., Maris J.M., Billups C., Smith M.A. Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program. Pediatr. Blood Cancer 2012, 58:191-199.
47. Grewal I.S., Flavell R.A. CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol. 1998, 16:111-135.
48. Khong A., Nelson D.J., Nowak A.K., Lake R.A., Robinson B.W. The use of agonistic anti-CD40 therapy in treatments for cancer. Int. Rev. Immunol. 2012, 31:246-266.
49. Jiang Q., Weiss J.M., Back T., Chan T., Ortaldo J.R., Guichard S., Wiltrout R.H. MTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment. Cancer Res. 2011, 71:4074-4084.
50. Holt S.V., Logie A., Davies B.R., Alferez D., Runswick S., Fenton S., Chresta C.M., Gu Y., Zhang J., Wu Y.L., Wilkinson R.W., Guichard S.M., Smith P.D. Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055). Cancer Res. 2012, 72:1804-1813.
51. Huang S., Yang Z.J., Yu C., Sinicrope F.A. Inhibition of mTOR kinase by AZD8055 can antagonize chemotherapy-induced cell death through autophagy induction and down-regulation of p62/sequestosome 1. J. Biol. Chem. 2011, 286:40002-40012.
52. Pike K.G., Malagu K., Hummersone M.G., Menear K.A., Duggan H.M., Gomez S., Martin N.M., Ruston L., Pass S.L., Pass M. Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014. Bioorg. Med. Chem. Lett. 2013, 23:1212-1216.
53. Bhagwat S.V., Gokhale P.C., Crew A.P., Cooke A., Yao Y., Mantis C., Kahler J., Workman J., Bittner M., Dudkin L., Epstein D.M., Gibson N.W., Wild R., Arnold L.D., Houghton P.J., Pachter J.A. Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Mol. Cancer Ther. 2011, 10:1394-1406.
54. Carayol N., Vakana E., Sassano A., Kaur S., Goussetis D.J., Glaser H., Druker B.J., Donato N.J., Altman J.K., Barr S., Platanias L.C. Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc. Natl. Acad. Sci. USA 2010, 107:12469-12474.
55. Altman J.K., Sassano A., Kaur S., Glaser H., Kroczynska B., Redig A.J., Russo S., Barr S., Platanias L.C. Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors. Clin. Cancer Res. 2011, 17:4378-4388.
56. Gupta M., Hendrickson A.E., Yun S.S., Han J.J., Schneider P.A., Koh B.D., Stenson M.J., Wellik L.E., Shing J.C., Peterson K.L., Flatten K.S., Hess A.D., Smith B.D., Karp J.E., Barr S., Witzig T.E., Kaufmann S.H. Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Blood 2012, 119:476-487.
57. Cassell A., Freilino M.L., Lee J., Barr S., Wang L., Panahandeh M.C., Thomas S.M., Grandis J.R. Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models. Neoplasia 2012, 14:1005-1014.
58. Liu Q., Chang J.W., Wang J., Kang S.A., Thoreen C.C., Markhard A., Hur W., Zhang J., Sim T., Sabatini D.M., Gray N.S. Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benz o[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. J. Med. Chem. 2010, 53:7146-7155.
59. Liu Q., Wang J., Kang S.A., Thoreen C.C., Hur W., Ahmed T., Sabatini D.M., Gray N.S. Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer. J. Med. Chem. 2011, 54:1473-1480.
60. Liu Q., Xu C., Kirubakaran S., Zhang X., Hur W., Liu Y., Kwiatkowski N.P., Wang J., Westover K.D., Gao P., Ercan D., Niepel M., Thoreen C.C., Kang S.A., Patricelli M.P., Wang Y., Tupper T., Altabef A., Kawamura H., Held K.D., Chou D.M., Elledge S.J., Janne P.A., Wong K.K., Sabatini D.M., Gray N.S. Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR. Cancer Res. 2013, 73:2574-2586.
61. Yu K., Toral-Barza L., Shi C., Zhang W.G., Lucas J., Shor B., Kim J., Verheijen J., Curran K., Malwitz D.J., Cole D.C., Ellingboe J., Ayral-Kaloustian S., Mansour T.S., Gibbons J.J., Abraham R.T., Nowak P., Zask A. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res. 2009, 69:6232-6240.
62. Wander S.A., Hennessy B.T., Slingerland J.M. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J. Clin. Invest. 2011, 121:1231-1241.
63. Naing A., Aghajanian C., Raymond E., Olmos D., Schwartz G., Oelmann E., Grinsted L., Burke W., Taylor R., Kaye S., Kurzrock R., Banerji U. Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. Br. J. Cancer 2012, 107:1093-1099.
64. Asahina H., Nokihara H., Yamamoto N., Yamada Y., Tamura Y., Honda K., Seki Y., Tanabe Y., Shimada H., Shi X., Tamura T. Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study. Invest. New Drugs 2012.
65. Weigelt B., Warne P.H., Downward J. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene 2011, 30:3222-3233.
66. Wang X., Sun S.Y. Enhancing mTOR-targeted cancer therapy. Expert Opin. Ther. Targets 2009, 13:1193-1203.
67. Rodrik-Outmezguine V.S., Chandarlapaty S., Pagano N.C., Poulikakos P.I., Scaltriti M., Moskatel E., Baselga J., Guichard S., Rosen N. MTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov. 2011, 1:248-259.
68. Hoang B., Benavides A., Shi Y., Yang Y., Frost P., Gera J., Lichtenstein A. The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of rapamycin complex 1 (TORC1)/eukaryotic translation initiation factor 4E (eIF-4E)/RAF pathway and activation is a mechanism of resistance. J. Biol. Chem. 2012, 287:21796-21805.
69. Dormond-Meuwly A., Roulin D., Dufour M., Benoit M., Demartines N., Dormond O. The inhibition of MAPK potentiates the anti-angiogenic efficacy of mTOR inhibitors. Biochem. Biophys. Res. Commun. 2011, 407:714-719.